Antibodies that are a fraction of the size of a regular antibody protect against key toxins in snake venom and could potentially replace 130-year-old treatments.
Small antibodies called nanobodies produced in camels, llamas, and alpacas might help stop the spread of COVID-19, but can they stand up against the competition?
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?